Adherence with epinephrine autoinjector prescriptions in primary care

Allergy, Asthma & Clinical Immunology

SHORT REPORT

 

OPEN ACCESS

• Elissa M. AbramsEmail author,
• Alexander G. Singer,
• Lisa Lix,
• Alan Katz,
• Marina Yogendran and
• F. Estelle R. Simons

Allergy, Asthma & Clinical Immunology201713:46

https://doi.org/10.1186/s13223-017-0218-5

Abstract

Background

The aim of this study was to estimate primary adherence for epinephrine autoinjector (EA) prescriptions in primary care practices in Manitoba, Canada.

Payments by US pharmaceutical and medical device manufacturers to US medical journal editors: retrospective observational study

BMJ 2017; 359 doi: https://doi.org/10.1136/bmj.j4619 (Published 26 October 2017)

Cite this as: BMJ 2017;359:j4619

• Article
• Related content
• Metrics
• Responses
• Peer review

1. Jessica J Liu, internist and assistant professor1 2,
2. Chaim M Bell, internist and professor1 2 3 4,
3. John J Matelski, biostatistician2,
4. Allan S Detsky, internist and professor1 2 3,
5. Peter Cram, internist and professor1 2 3 4

Author affiliations

1. Correspondence to: J J Liu Department of Medicine, Division of General Internal Medicine, University Health Network and Sinai Health System, Toronto, Ontario, Canada jessica.liu@uhn.ca

EAACI Guidelines on Allergen Immunotherapy (AIT)

EAACI has a long history and strong ethos in implementing the latest research findings to deliver better healthcare for patients with allergies. Over the last decades this mission has become even more important with allergic diseases now affecting the lives of millions of people around the world. This represents a major burden for patients as well as their clinicians, governments, legislators and regulators. The current challenge is to deliver appropriate treatments that are able to prevent lifetime disabilities, shifting from “treating a disease“ to “promote health” in a sustainable context.

Allergen immunotherapy (AIT) has been used for a century. Several terms including “desensitization”, “hyposensitization“ and “vaccines” have been used, and often misused, to indicate administration of incremental doses of allergenic substances to reduce the clinical manifestations of allergy. However AIT has also been the subject of considerable controversy in terms of its efficacy. The dispute has impacted on the dissemination of knowledge about AIT, the availability of the products in many countries and the relevant policies for their reimbursement. Some of these issues result from an inadequate translation of the scientific data into daily practice, with clinical judgment being established on expert opinion instead of the objective evaluation of valid scientific studies.

Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies

November–December, 2017Volume 5, Issue 6, Pages 1519–1531

Mark Boguniewicz, MDCorrespondence information about the author MD Mark BoguniewiczEmail the author MD Mark Boguniewicz

, 

Andrew F. Alexis, MD, MPH

, 

Lisa A. Beck, MD

, 

Julie Block, BA

, 

Lawrence F. Eichenfield, MD

, 

Luz Fonacier, MD

, 

Emma Guttman-Yassky, MD, PhD

, 

Amy S. Paller, MD

, 

David Pariser, MD

, 

Jonathan I. Silverberg, MD, PhD, MPH

, 

Mark Lebwohl, MD

Open AccessExpert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies

DOI: http://dx.doi.org/10.1016/j.jaip.2017.08.005

 |

Article Info

• Abstract

• Full Text
• Images
• References

Atopic dermatitis (AD) is a common, chronic, relapsing, inflammatory skin disease that affects children and adults. Until recently, the only Food and Drug Administration–approved systemic treatment option for patients with moderate-to-severe AD was systemic steroids, which are not recommended by current guidelines and are commonly associated with disease rebound.

Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology

Volume 72, Issue 11November 2017 Pages 1657–1665

POSITION PAPER

P. W. Hellings, L. Klimek, C. Cingi, I. Agache, C. Akdis, C. Bachert, J. Bousquet, P. Demoly, P. Gevaert, V. Hox, C. Hupin, L. Kalogjera, F. Manole, R. Mösges, J. Mullol, N. B. Muluk, A. Muraro, N. Papadopoulos, R. Pawankar, C. Rondon, M. Rundenko, S. F. Seys, E. Toskala, L. Van Gerven, L. Zhang, N. Zhang, W. J. Fokkens

Abstract

This EAACI position paper aims at providing a state-of-the-art overview on nonallergic rhinitis (NAR). A significant number of patients suffering from persistent rhinitis are defined as nonallergic noninfectious rhinitis (NANIR) patients, often denominated in short as having NAR. NAR is defined as a symptomatic inflammation of the nasal mucosa with the presence of a minimum of two nasal symptoms such as nasal obstruction, rhinorrhea, sneezing, and/or itchy nose, without clinical evidence of endonasal infection and without systemic signs of sensitization to inhalant allergens.

Methotrexate Versus Cyclosporine in Adults with Moderate-to-Severe Atopic Dermatitis: A Phase III Randomized Noninferiority Trial

Catherine Goujon, MDCorrespondence information about the author MD Catherine GoujonEmail the author MD Catherine Goujon

, 

Manuelle Viguier, MD, PhD

, 

Delphine Staumont-Sallé, MD, PhD

, 

Claire Bernier, MD

, 

Gérard Guillet, MD, PhD

, 

Morad Lahfa, MD

, 

Marie-Christine Ferrier Le Bouedec, MD

, 

Frédéric Cambazard, MD, PhD

, 

David Bottigioli, BA

, 

Sophie Grande, MD

, 

Karima Dahel, MD

, 

Frédéric Bérard, MD, PhD

, 

Muriel Rabilloud, MD, PhD

, 

Catherine Mercier, PhD

, 

Jean-François Nicolas, MD, PhD

PlumX Metrics

DOI: http://dx.doi.org/10.1016/j.jaip.2017.07.007

Article Info

• Abstract

• Full Text
• Images
• References

Background

Methotrexate is currently used to treat atopic dermatitis but has never been assessed versus cyclosporine in adults.

Objective

This study evaluated the efficacy and safety of methotrexate versus cyclosporine in patients with moderate-to-severe atopic dermatitis.

Chronic Spontaneous Urticaria: Pathogenesis and Treatment Considerations

Allergy Asthma Immunol Res. 2017 Nov;9(6):477-482. https://doi.org/10.4168/aair.2017.9.6.477

Allen P. Kaplan

Department of Medicine, Division of Pulmonary and Critical Care Medicine, Allergy and Clinical Immunology, Medical University of South Carolina, Charleston, SC, USA.

Correspondence to: Allen P. Kaplan, MD, Department of Medicine, Division of Pulmonary and Critical Care Medicine, Allergy and Clinical Immunology, Medical University of South Carolina, Charleston, 171 Ashley Avenue, Charleston, SC 29425, USA. Tel: +1-843-729-0264; Fax: +1-843-722-1253; Email: kaplana@musc.edu

Go to: Abstract

The treatment of chronic spontaneous urticaria begins with antihistamines; however, the dose required typically exceeds that recommended for allergic rhinitis. Second-generation, relatively non-sedating H1-receptor blockers are typically employed up to 4 times a day.

Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real-world database analysis

• 
  
  Open Access
• Creative Commons

ORIGINAL ARTICLE

Authors

• DOI: 10.1111/all.13213  View/save citation
• Abstract
  Background

  Allergy immunotherapy (AIT) is the only treatment for allergic rhinitis (AR) and/or allergic asthma (AA) with long-term efficacy. However, there are few real-life data on the progression of AR and/or AA in patients receiving AIT.